Description
About the Compound
Tirzepatide is a dual incretin receptor agonist that targets both GLP-1 and GIP pathways, delivering documented results in metabolic health, weight optimization and insulin-sensitivity regulation. It is investigated in metabolic-syndrome and obesity research contexts.
Documented Activity Profile
- Dual GLP-1 / GIP agonist
- Documented exceptional metabolic and weight-optimization results
- Investigated for insulin-sensitivity regulation
Specifications
- 20mg per vial β lyophilized powder
- HPLC verified at 99%+ purity
- Third-party tested & COA verified per batch
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT A DRUG, FOOD, OR COSMETIC. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

Reviews
There are no reviews yet.